AbbVie presents Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis at EADV 2026

By Public Technologies
  • AbbVie flagged new dermatology trial and real-world results slated for presentation at the 2026 EADV Congress in Vienna, Sept. 30-Oct. 3.
  • Late-breaking Phase 2 findings for investigational zumilokibart in moderate-to-severe atopic dermatitis are set to outline efficacy and safety.
  • Late-breaking data for investigational lutikizumab in hidradenitis suppurativa are expected to show activity against key inflammatory drivers.
  • Updated evidence for Skyrizi and Rinvoq across multiple immune-mediated skin diseases is due to reinforce performance across broader patient groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609300100PR_NEWS_USPR_____CG57265) on September 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk